Presage Biosciences Appoints Oncology Experts to Newly Created Medical Advisory Panel

Seattle – January 11, 2016 – Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the formation of a Medical Advisory Panel to provide guidance on research and development strategies for Presage’s portfolio of novel oncology therapies.

“It is our pleasure to welcome a group of leaders in cancer research and clinical practice to our newly formed Medical Advisory Panel,” said Nathan Caffo, President of Presage. “With expertise spanning a range of cancers, the panel will be instrumental in understanding the evolving treatment paradigms in these cancers and guiding our efforts to use our CIVO™ predictive in vivo assessment technology to develop novel therapies and combinations to better treat patients with cancer. We look forward to working with the panel beginning with voruciclib, a clinical-stage oral CDK inhibitor that we are developing in combination with other FDA approved agents.”

Inaugural members of Presage’s Medical Advisory Panel, led by Dr. Keith Flaherty include:

- **Keith T. Flaherty, M.D.** Director of Developmental Therapeutics in the Cancer Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research is focused on understanding and developing targeted therapies for cancer with a particular focus on disrupting signal transduction pathways in melanoma.
- **Ghassan Abou-Alfa, M.D.,** Memorial Sloan Kettering Cancer Center, Associate Professor of Medicine at Weill Cornell Medical College and the current chair of the National Cancer Institute (NCI) hepatobiliary Task Force. Dr. Abou-Alfa is a renowned authority on primary liver cancer (hepatocellular cancer).
- **Carlos L. Arteaga, M.D.,** Director of the Center for Cancer Targeted Therapies and the Breast Cancer Program and the Donna S. Hall Chair in Breast Cancer Research and Professor of Medicine and Cancer Biology at Vanderbilt-Ingram Cancer Center of Vanderbilt University. Dr. Arteaga has a wealth of experience in oncogene signaling in breast cancer cells, mechanisms of drug resistance, and translational breast cancer research.
- **Manuel Hidalgo, M.D., Ph.D.,** Clinical Director of the Cancer Center and Chief of Hematology-Oncology at Beth Israel Deaconess Medical Center and transitioning from Director of the Clinical Research Program and Vice Director of Translational Research at Centro Nacional de Investigaciones Oncológicas (CNIO; Spanish National Cancer Research Center) in Spain. Dr. Hidalgo has led groundbreaking research amounting to key advances in treating pancreatic cancer.
• **Ian E. Krop, M.D., Ph.D.**, Chair of Breast Medical Oncology and the Director of Breast Cancer Clinical Research at the Dana-Farber Cancer Institute/Harvard Cancer Center and Assistant Professor of Medicine at Harvard Medical School. Dr. Krop is focused on developing novel targeted breast cancer therapies and working to understand resistance to HER2-targeted therapies.

• **Robert G. Maki, M.D., Ph.D.**, Director of Translational Oncology at SARC (Sarcoma Alliance for Research through Collaboration) and Mount Sinai Medical Center, Professor of Medicine, Pediatrics, and Orthopaedics and the Steven Ravitch Chair in Pediatric Hematology-Oncology. Dr. Maki’s current focus is translational sarcoma research and treatment of soft tissue and bone sarcomas.

• **Eileen M. O’Reilly, M.D.**, Medical Oncologist and Faculty Member at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College and co-chair for the gastrointestinal group of the Alliance Co-operative group. Dr. O’Reilly is an authority in pancreatic cancer research and treatment with additional expertise in esophageal, gastric, hepatobiliary, and colorectal cancers.

• **Mark Pegram, M.D.**, Director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center, Co-Director of Stanford’s Molecular Therapeutics Program, and Associate Director for Clinical Research, Stanford Cancer Institute at Stanford University. Dr. Pegram is currently focused on breast cancer molecular therapeutics.

• **Anas Younes, M.D.**, Chief of Lymphoma Service at Memorial Sloan Kettering Cancer Center. Dr. Younes is focused on developing novel targeted therapies for the treatment of Hodgkin and non-Hodgkin lymphoma.

• **Andrew X. Zhu, M.D., Ph.D.**, Director of Liver Cancer Research at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. The major focus of Dr. Zhu’s research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma through Phase I, II, and III clinical trials.

“Comprised of a highly accomplished group of physicians from leading institutions across the country, the Presage Medical Advisory Panel will provide invaluable insights as we design clinical trials for drug combinations that can demonstrate efficacy and reflect the needs of underserved patient populations,” said Richard Klinghoffer, PhD., Chief Scientific Officer of Presage. “We’re particularly interested in establishing how we can best employ CIVO™ to deliver valuable in vivo data to predict systemic response in order to reduce the current high risk of failure during early-stage trials.”

Presage has developed CIVO™, a predictive in vivo assessment technology for drug development that enables the first side-by-side comparison of multiple drugs and combinations within a single living tumor while still in a patient’s body, without exposing the patient to the toxicity of systemic dosing. Presage is actively in-licensing promising compounds and using CIVO™ to develop a portfolio of proprietary oncology therapies.

CIVO™ was shown to accurately predict systemic response to oncology drugs in multiple experiments in human xenografted mouse models. Additional results in canine patients and a first-in-human study in lymphoma patients are summarized in a study published in the April 2015 issue of *Science Translational Medicine* by researchers at Fred Hutchinson Cancer Research Center and Presage Biosciences.
About Presage Biosciences

Presage Biosciences is an oncology company pioneering the incorporation of human efficacy data much earlier in the drug development and clinical trial processes with its patented CIVO™ arrayed microinjection platform. The CIVO platform allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance and drug synergies in the tumor’s native microenvironment. Presage is using CIVO™ to develop a portfolio of promising oncology therapies to advance to the clinic, including voruciclib, a clinical-stage oral CDK inhibitor in clinical development for multiple cancer indications. Presage also partners with oncology-focused pharmaceutical companies through strategic alliances to provide in vivo data to validate novel targets, promote drug candidates to the right indications and discover effective drug combinations. Presage is privately held and based in Seattle. For more information, visit www.presagebio.com.

# # #

Media Contact:
Kathryn Morris
PR On Call
845-635-9828
kathryn@proncall.com